Close

Professor Andrew Briggs

BSc (Hons) MSc DPhil

Professor

LSHTM
15-17 Tavistock Place
London
WC1H 9SH
United Kingdom

Professor of Health Economics at the London School of Hygiene & Tropical Medicine, I  previously held the William R Lindsay Chair in Health Economics at the University of Glasgow. Following a sabbatical at Memorial Sloan Kettering Cancer Center, New York in 2016/17, I remain a Visiting Investigator, collaborating with Dr Peter Bach on value frameworks for oncology medications.

I have  co-authored two textbooks, one published by OUP entitled Decision Modelling for Health Economic Evaluation, and another published by Wiley entitled Statistical Methods for Cost-Effectiveness Analysis.

A link to my GooGle Scholar page: https://bit.ly/GS-briggs

Affiliations

Department of Health Services Research and Policy
Faculty of Public Health and Policy

Centres

Centre for Evaluation
Centre for Statistical Methodology

Research

My main methodological focus of research has been health economic evaluation, particularly statistical methods for cost-effectiveness analysis.  This includes statistical methods for estimation of parameters for cost-effectiveness models as well as statistical analysis of cost-effectiveness alongside clinical trials.  I have a more general interest in epidemiological methods, in particular the use of prognostic scoring methods for predicting health outcomes and the relationship with heterogeneity in cost-effectiveness analysis.

Research Area
Decision analysis
Economic evaluation
Randomised controlled trials
Discipline
Health economics
Country
United Kingdom
United States of America
South Africa
Region
European Union
North America
Sub-Saharan Africa (all income levels)

Selected Publications

Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
Bhatt DL; Briggs AH; Reed SD; Annemans L; Szarek M; Bittner VA; Diaz R; Goodman SG; Harrington RA; Higuchi K
2020
Journal of the American College of Cardiology
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma.
Briggs A; Daniele B; Dick K; Evans TRJ; Galle PR; Hubner RA; Lopez C; Siebert U; Tremblay G
2020
BRITISH JOURNAL OF CANCER
Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data.
Dakin HA; Leal J; Briggs A; Clarke P; Holman RR; Gray A
2020
Medical decision making : an international journal of the Society for Medical Decision Making
Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review.
Hájek R; Gonzalez-McQuire S; Szabo Z; Delforge M; DeCosta L; Raab MS; Bouwmeester W; Campioni M; Briggs A
2020
BMJ open
Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost
Hu Y; Briggs A; Gennarelli RL; Bartlett EK; Ariyan CE; Coit DG; Brady MS
2020
Annals of Surgical Oncology
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer.
Huang M; O'Shaughnessy J; Zhao J; Haiderali A; Cortes J; Ramsey S; Briggs A; Karantza V; Aktan G; Qi CZ
2020
Journal of the National Comprehensive Cancer Network : JNCCN
See more Publications